Oncology

How do ACOs reach the point of delivering both savings and better care? The recent online session of the ACO and Emerging Healthcare Delivery Coalition, sponsored by The American Journal of Managed Care, covered how ACOs evolve, how that process applies to oncology care, and how managed care can benefit from a better model for mental health delivery.

In order to reign in high costs of care in oncology, the healthcare community needs to be able to define value better, according to Alex Bastian, MBA, senior vice president at GfK.

The pilot, which will has been launched for head and neck cancer patients, will include quality measures to ensure adequate patient care.

With the immuno-oncology field getting more intense, Pfizer continues its struggle to gain a foothold in the field. Following unsuccessful attempts to bid for AstraZeneca, Pfizer has now signed a deal with a Belgian company, iTeos Therapeutics.

Should e-cigarettes be regulated he same way as cigarettes? Should marketing and sales restrictions be the same? Policy and health experts chime-in.

Just prior to the FDA guidance on the use of power morcellators, Johns Hopkins made public a new care plan for managing fibroids or hysterectomies in women over age 50 years.

Immune response boosters in oncology, approved for melanoma so far, are being evaluated in several different cancer types. While the drugs perform well, there is a definite need to identify responsive patient cohorts.

A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.

Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery for DCIS.

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was 2-and-a-half, shares the challenging and painful experiences of battling the disease.

Palliative principles were applied to the care of more HH patients than non-HH patients, but no differences were found in their utilization of healthcare services.

Even in a fully integrated healthcare system, only 28% of cancer quality measures could be validated by using electronically available data.

A majority of breast cancer patients in the US are receiving longer radiation therapy than is necessary and compared with their counterparts in other countries, according to a new study published in JAMA.

Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.

On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.